This section hosts video presentations from past key congresses. Satellite symposia from the World Psoriasis & Psoriatic Arthritis Conference in 2015, Psoriasis from Gene to Clinic International Congress in 2014 and successive EADV meetings from 2013 to 2016 are featured. Read about each event and follow the link to view the associated presentations.
This page will regularly be updated with videos from future congresses as they become available.
The 25th congress of the European Academy of Dermatology and Venereology was held in Vienna, Austria from 28th September–2nd October 2016.
The Novartis-sponsored satellite symposium, ‘Psoriatic Disease – Skin or Joint, it’s about the Patient’, chaired by Richard Warren (University of Manchester and Salford Royal NHS Foundation Trust, UK), is available as separate presentations and videos for you to view. These focus on the understanding of current trends in patient care, responses to treatment, and developing novel treatment regimes. In particular, the speakers discuss the use of IL–17A antagonists to reduce psoriatic disease symptoms and improve quality of life.
The 24th congress of the European Academy of Dermatology and Venereology was held in Copenhagen, Denmark from 7–11 October 2015.
The Novartis-sponsored satellite symposium, ‘The New Generation of Psoriasis Treatments – Assessing the Potential Impact of the Latest Therapeutic Monoclonal Antibodies’, chaired by Kristian Reich (Georg-August-University Göttingen, Germany and Dermatologikum Hamburg, Germany), is available in full or as separate presentations for you to view. Focusing on the growing number of targeted therapies in psoriasis, the faculty discuss the efficacy and safety of these new and emerging treatment options, and how they should be integrated into the real-world clinical environment.
The 4th World Psoriasis & Psoriatic Arthritis Conference was held in Stockholm, Sweden from 8–11 July 2015 and focused on the future of care and treatment for patients with psoriasis and psoriatic arthritis.
The Novartis-sponsored satellite symposium, ‘Meeting patient needs in psoriasis and psoriatic arthritis: Current evidence’, chaired by Bruce Kirkham (Consultant Rheumatologist, Department of Rheumatology, Guy’s & St Thomas’ NHS Foundation Trust, London, UK), is available in full or as separate presentations for you to view. This symposium sought to challenge current thinking in the management of psoriasis and discussed emerging perspectives in the treatment of psoriatic arthritis.
The 7th International Psoriasis From Gene to Clinic Congress was held in London, UK from 11th–13th December 2014. Sessions were dedicated to key scientific and clinical questions in psoriasis, with invited speakers discussing issues at the cutting edge of research in their field.
The Novartis-sponsored satellite symposium 'Selective IL·17A Inhibition: A Targeted Approach to Psoriasis Therapy', chaired by Richard B. Warren (Senior Lecturer and Honorary Consultant Dermatologist, University of Manchester, Manchester, UK), is available in full or as separate presentations for you to view. In this symposium, leading experts critically assessed safety, efficacy, comorbidity and quality of life data regarding inhibition of IL-17A as a therapeutic strategy for the management of psoriasis.
The 23rd congress of the European Academy of Dermatology and Venereology was held in Amsterdam, The Netherlands, from 8th–12th October 2014. The congress was attended by delegates from around the world, with sessions spanning across all fields of dermatology and venereology.
The Novartis-sponsored satellite symposium 'Revealing a Clear Path Towards a New Era in the Management of Psoriasis', chaired by Chris Griffiths (Professor of Dermatology, Dean of Research, University of Manchester, Manchester, UK), is available in full or as separate presentations for you to view. This educational symposium provided an overview of the scientific rationale for inhibiting the IL-17A pathway and discussed how clinical data translates into effective treatment and meaningful improvements in health-related quality of life for patients with psoriasis.
The 22nd congress of the European Academy of Dermatology and Venereology was held in the city of Istanbul, Turkey and was themed ‘Dermatovenereology in a changing world’.
The Novartis-sponsored satellite symposium 'IL-17A: A New Era for Psoriasis Patients', chaired by Richard Langley (Director of Research, Division of Clinical Dermatology & Cutaneous Science, Dalhousie University, Nova Scotia, Canada), is available in full or as separate presentations for you to view. In this symposium, study investigators discussed newly released phase 3 data from the secukinumab development programme, including data on the feasibility of flexible treatment approaches for the maintenance of disease control.